共 183 条
[1]
West HJ(2015)Immune checkpoint inhibitors JAMA Oncol 1 115-115
[2]
Eun Y(2019)Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab Sci Rep 9 14039-1183
[3]
Kim IY(2017)Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review Immunotherapy 9 1175-2697
[4]
Sun J-M(2012)Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol: Off J Am Soc Clin Oncol 30 2691-68
[5]
Abdel-Rahman O(2019)Immune dysregulation in cancer patients developing immune-related adverse events Br J Cancer 120 63-3714
[6]
Eltobgy M(2018)High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma Cancer 124 3706-2878
[7]
Oweira H(2018)Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer J Clin Oncol 36 2872-306
[8]
Giryes A(2019)Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors J Immunother Cancer 7 306-1775
[9]
Tekbas A(2018)Early use of systemic corticosteroids in patients with advanced nsclc treated with nivolumab J Thorac Oncol 13 1771-e000457
[10]
Decker M(2019)Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors ESMO Open 4 e000457-e180798